CYP3A4 and cancer: Furthermore, everolimus dosing in cancer is much higher than in transplant patients (i.e. 5–10 mg/day versus 2-5mg/day), thus, it is conceivable that in the cancer setting, CYP3A4*22 might exert a greater and more clinical relevant effect on drug toxicity than in the transplant setting.